US Patent for Oral Mucositis Drug

| By | Drug Patents

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent & Trademark Office issued a new patent to the Company for the treatment of oral mucositis. The patent (U.S. Patent Number 10206894) covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts.

The new patent broadens the Company’s Intellectual Property footprint in the oral mucositis therapeutic area, and further builds on other recently assigned patent protections for Brilacidin, the Company’s defensin-mimetic drug candidate. Brilacidin has been successfully evaluated in clinical trials in oral mucositis, inflammatory bowel disease and serious skin infections, with planned extension into dermatological diseases.

Recent patents assigned to Brilacidin include: a patent covering Brilacidin oral, buccal and sublingual pharmaceutical compositions, including liquid compositions, such as rinses; a patent covering Brilacidin in combination with additional medicaments, such as antibiotics, anti-inflammatory agents, etc.

As the Company prepares to advance Brilacidin into Phase 3 development for the prevention and treatment of oral mucositis, initially in Head and Neck Cancer, this new patent provides additional key protections. Oral mucositis represents a large area of unmet need and a substantial market opportunity. We, along with potential Pharma partners, feel Brilacidin—as a conveniently-administered oral rinse—is well-positioned possibly to emerge one day as a frontline, go-to treatment for this common, costly and debilitating side-effect of chemoradiation

commented Arthur P. Bertolino,
MD, PhD, MBA, President and Chief
Medical Officer at Innovation Pharmaceuticals.